DK0781279T3 - Quinoxalindion-NMDA-receptorantagonister - Google Patents

Quinoxalindion-NMDA-receptorantagonister

Info

Publication number
DK0781279T3
DK0781279T3 DK95931989T DK95931989T DK0781279T3 DK 0781279 T3 DK0781279 T3 DK 0781279T3 DK 95931989 T DK95931989 T DK 95931989T DK 95931989 T DK95931989 T DK 95931989T DK 0781279 T3 DK0781279 T3 DK 0781279T3
Authority
DK
Denmark
Prior art keywords
pct
alkyl
group
date mar
ch2ch3
Prior art date
Application number
DK95931989T
Other languages
English (en)
Inventor
Alan Stobie
Charles Eric Mowbray
David John Bull
Christopher Lee Carr
Michael Johnathan Fray
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of DK0781279T3 publication Critical patent/DK0781279T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK95931989T 1994-09-13 1995-09-01 Quinoxalindion-NMDA-receptorantagonister DK0781279T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418443A GB9418443D0 (en) 1994-09-13 1994-09-13 Therapeutic agents
PCT/EP1995/003483 WO1996008485A1 (en) 1994-09-13 1995-09-01 Quinoxalinedione nmda receptor antagonists

Publications (1)

Publication Number Publication Date
DK0781279T3 true DK0781279T3 (da) 2001-09-03

Family

ID=10761258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95931989T DK0781279T3 (da) 1994-09-13 1995-09-01 Quinoxalindion-NMDA-receptorantagonister

Country Status (14)

Country Link
US (1) US5783572A (da)
EP (1) EP0781279B1 (da)
JP (1) JP2898097B2 (da)
AT (1) ATE202099T1 (da)
CA (1) CA2199845C (da)
DE (1) DE69521323T2 (da)
DK (1) DK0781279T3 (da)
ES (1) ES2158126T3 (da)
FI (1) FI113471B (da)
GB (1) GB9418443D0 (da)
GR (1) GR3036270T3 (da)
MX (1) MX9701894A (da)
PT (1) PT781279E (da)
WO (1) WO1996008485A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
AU5367598A (en) * 1996-11-25 1998-06-22 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
DE19936521A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN103497114A (zh) * 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
CN103328452A (zh) * 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
EP0647137B1 (en) * 1992-06-22 2008-08-13 The Regents Of The University Of California Glycine receptor antagonists and the use thereof

Also Published As

Publication number Publication date
PT781279E (pt) 2001-09-28
DE69521323T2 (de) 2001-09-20
FI971026A0 (fi) 1997-03-12
WO1996008485A1 (en) 1996-03-21
EP0781279A1 (en) 1997-07-02
FI971026A (fi) 1997-03-12
CA2199845A1 (en) 1996-03-21
US5783572A (en) 1998-07-21
GB9418443D0 (en) 1994-11-02
EP0781279B1 (en) 2001-06-13
FI113471B (fi) 2004-04-30
GR3036270T3 (en) 2001-10-31
MX9701894A (es) 1997-06-28
DE69521323D1 (de) 2001-07-19
ES2158126T3 (es) 2001-09-01
JPH09511523A (ja) 1997-11-18
ATE202099T1 (de) 2001-06-15
JP2898097B2 (ja) 1999-05-31
CA2199845C (en) 2000-08-01

Similar Documents

Publication Publication Date Title
DK0781279T3 (da) Quinoxalindion-NMDA-receptorantagonister
ZA928682B (en) Acyclic ethylenediamine derivatives
FI962753A (fi) Menetelmä lääkeaineena käytt¦kelpoisen piperidyyli- tai pyrrolidiinijohdannaisen tai sen farmaseuttisen suolan valmistamiseksi
DE69409525T2 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
NZ508910A (en) Di-substituted piperazine or piperidine derivatives useful as muscarinic antagonists
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
DE69528485D1 (de) Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE69402981D1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazine als 5ht1a ligande
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
DK0510003T3 (da) Piperidin-og pyrrolidinderivater
ATE214056T1 (de) Benzodiazepinderivate
DK0553278T3 (da) 2-Phenyl- og 2-thienyl-(2)-piperidinderivater med neurobeskyttende egenskaber
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse
UY24465A1 (es) Antagonistas oxadiazol y tiadiazol del receptor muscarinico